Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Assets (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Non-Current Assets for 7 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 367.38% to $9.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 367.38% increase, with the full-year FY2025 number at $9.1 million, up 367.38% from a year prior.
  • Other Non-Current Assets was $9.1 million for Q4 2025 at Kymera Therapeutics, up from $5.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $9.1 million in Q4 2025 to a low of $716000.0 in Q3 2021.
  • A 5-year average of $4.0 million and a median of $3.2 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 20286.67% in 2021, then crashed 67.44% in 2024.
  • Kymera Therapeutics' Other Non-Current Assets stood at $6.1 million in 2021, then rose by 0.23% to $6.1 million in 2022, then decreased by 5.2% to $5.8 million in 2023, then plummeted by 66.44% to $2.0 million in 2024, then surged by 367.38% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Other Non-Current Assets are $9.1 million (Q4 2025), $5.8 million (Q2 2025), and $3.3 million (Q1 2025).